港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

派格生物医药-B

60.700

-2.550-4.03%

成交量：83.76万

成交额：5,355.15万

市值：234.30亿

市盈率：-71.90

高：72.750

开：72.700

低：55.050

收：63.250

52周最高：72.750

52周最低：8.680

股本：3.86亿

香港流通股本：2.79亿

量比：4.00

换手率：0.30%

股息：- -

股息率：- -

每股收益(LYR):-0.844

净资产收益率：-224.15%

总资产收益率：-61.30%

市净率：83.98

市盈率(LYR):-71.90

市销率: -5531.09

数据加载中...

总览公司新闻资讯公告

港股异动 | 派格生物医药-B(02565)高开近15% 核心产品PB-119新药上市申请获批

派格生物长效 GLP-1“维培那肽”获批上市

一周港股牛熊榜 | 减肥药赛道升温，歌礼一周飙45%；进入“万店俱乐部”，沪上阿姨涨31%；月活跃用户减少，腾讯音乐跌14%

老虎资讯综合

派格生物医药-B(02565)：中国国家药监局批准PB-119新药上市申请

港股异动 | 派格生物医药-B(02565)尾盘涨超12% 核心产品维培那肽注射液获批上市

万亿价值拐点已至派格生物(02565)创新药“派达康®️”成功获批！

港股异动 | 派格生物医药-B(02565)最高涨超15% GLP-1减重药出海中东及非洲

Tides 周递 | 全球多肽和寡核苷酸药物一周要闻（10.30-11.7）

派格生物医药-B申请解散附属公司上海迈迹；恒瑞医药HRS-5965胶囊拟纳入优先审评｜医药早参

每日经济新闻

一周港股牛熊榜 | 中东、非洲收获好消息，创新药企派格生物本周飙13%；政策与周期双轮驱动，英诺赛科升超11%；利润暴跌，中兴通讯本周跌超18%

老虎资讯综合

港股异动 | 派格生物医药-B(02565)尾盘涨超20%再创新高近期授出糖尿病药物于中东及非洲独家许可

派格生物医药-B10月23日主力净流出140.8万元散户资金买入

派格生物医药-B(02565)：建议授出VISEPEGENATIDE (PB-119) 于中东及非洲的独家许可

派格生物医药-B：2025 中期报告

香港交易所

派格生物医药-B09月29日遭主力抛售102.8万元

派格生物医药-B09月26日主力净流出106.5万元散户资金买入

港股异动 | 派格生物医药-B(02565)午前涨超5% GLP-1多靶点领域临床进度靠前 PB-718为公司旗下重磅品种

派格生物医药-B09月19日主力净流出49.4万元散户资金买入

派格生物医药-B09月18日主力净流入91.6万元散户资金抛售

派格生物医药-B09月10日获主力加仓37.5万元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02565/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":60.7,"timestamp":1763366895008,"preClose":63.25,"halted":0,"volume":837550,"delay":0,"floatShares":279164339,"shares":386000000,"eps":-0.8441980807558668,"marketStatus":"已收盘","change":-2.55,"latestTime":"11-17 16:08:15","open":72.7,"high":72.75,"low":55.05,"amount":53551500,"amplitude":0.279842,"askPrice":60.7,"askSize":6500,"bidPrice":60.05,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.6567813121176553,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":63.25,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":3.995945,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":279164339,"roa":"-61.30%","roe":"-224.15%","lyrEps":-0.844198,"volumeRatio":3.995945,"shares":386000000,"dividePrice":0,"high":72.75,"amplitude":0.279842,"preClose":63.25,"low":55.05,"week52Low":8.68,"pbRate":"83.98","psRate":"-5531.09","week52High":72.75,"institutionHeld":0,"latestPrice":60.7,"committee":-0.733333,"eps":-0.8441980807558668,"divideRate":0,"volume":837550,"delay":0,"ttmEps":-0.6567813121176553,"open":72.7,"prevYearClose":15.6,"prevWeekClose":63.25,"prevMonthClose":60.1,"prevQuarterClose":54.2,"fiveDayClose":53.4,"twentyDayClose":52.05,"sixtyDayClose":30.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0,"sell":0,"strongSell":1,"meanLabel":"STRONG SELL","meanPercent":1,"analysts":1,"updateTime":1755187200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2025-11-14","current":-96.473383,"percent":0,"low":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"high":-11.114373,"avg":-37.222505,"sd":22.07937,"marketCap":17657144441},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441}],"updateTime":1763353808626},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584697958","title":"港股异动 | 派格生物医药-B(02565)高开近15% 核心产品PB-119新药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2584697958","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584697958?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 09:28","pubTimestamp":1763342919,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B高开近15%，截至发稿，涨14.94%，报72.7港元，成交额112.69万港元。消息面上，11月14日，派格生物医药-B发布公告，中国国家药品监督管理局已批准本公司核心产品PB-119的新药上市申请。该产品为国家科技重大专项认定为“重大新药创制”的国家原创1类新药。PB-119可显著改善β细胞功能，除血糖外，兼具全面管理患者的血压、血脂及体重，实现“四高共管，全面获益”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BLDYK493.USD","399441","BK1161","161726","BK4211","02565","PB","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2583663186","title":"派格生物长效 GLP-1“维培那肽”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583663186","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583663186?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 08:03","pubTimestamp":1763251394,"startTime":"0","endTime":"0","summary":"NMPA发布2025年11月14日药品批准证明文件送达信息，本批次共有129个受理号获批，其中：派格生物的维培那肽注射液获批上市，用于改善成人2型糖尿病患者的血糖控制。此外，维培那肽在降压、调脂等改善心血管危险因素方面均具有显著作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116084057a6fc31e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116084057a6fc31e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"1157409611","title":"一周港股牛熊榜 | 减肥药赛道升温，歌礼一周飙45%；进入“万店俱乐部”，沪上阿姨涨31%；月活跃用户减少，腾讯音乐跌14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157409611","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157409611?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 18:01","pubTimestamp":1763114515,"startTime":"0","endTime":"0","summary":"2589.HK本周上涨约 +31.4%，“沪上阿姨”成功进入“万店俱乐部”根据极海品牌监测数据显示，截至目前，“沪上阿姨”品牌全国门店数量已达10739家，成功进入“万店俱乐部”。该产品为国家科技重大专项认定为“重大新药创制”的国家原创1类新药。1698.HK本周下跌约 –14.28%，第三季non-IFRS净利润按年升逾32%惟月活跃用户减少消息面上，腾讯音乐第三季总收入84.63亿人民币(下同)，按年增长20.6%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01910","02473","02565","01698","01333","02570","00179","02026","01672","02589"],"gpt_icon":1},{"id":"2583575859","title":"派格生物医药-B(02565)：中国国家药监局批准PB-119新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2583575859","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583575859?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 16:35","pubTimestamp":1763109331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，中国国家药品监督管理局已批准本公司核心产品PB-119的新药上市申请。派达康为本公司开发的新一代长效胰高血糖素样肽-1受体激动剂，每周给药一次。该产品为国家科技重大专项认定为“重大新药创制”的国家原创1类新药。这一结构性修改使药物与GLP-1受体高效结合并发挥生物学效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IE00B64QTZ34.USD","BK4211","PB","161726","02565","IE00BLDYK493.USD","399441"],"gpt_icon":0},{"id":"2583578349","title":"港股异动 | 派格生物医药-B(02565)尾盘涨超12% 核心产品维培那肽注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583578349","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583578349?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 15:54","pubTimestamp":1763106841,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B(02565)尾盘涨超12%，截至发稿，涨12.59%，报63.5港元，成交额2820.11万港元。消息面上，由派格生物自主研发的周制剂GLP-1RA维培那肽(派达康®)正式获中国国家药监局批准上市，用于治疗2型糖尿病(T2DM)。根据弗若斯特沙利文数据，2018年至2023年，全球T2DM药物市场规模复合年增长率约为29.3%。GLP-1受体激动剂的市场份额显著增长，从2018年的约8.4%增长至2023年的约29.3%。长效GLP-1受体激动剂因其更高的依从性，预计将在2032年占据中国GLP-1受体激动剂市场80%以上的份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","02565","BK1161","161726"],"gpt_icon":0},{"id":"2583520250","title":"万亿价值拐点已至 派格生物(02565)创新药“派达康®️”成功获批！","url":"https://stock-news.laohu8.com/highlight/detail?id=2583520250","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583520250?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 15:40","pubTimestamp":1763106044,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创新药投资主线GLP-1赛道再度迎来标志性事件——派格生物自主研发的周制剂GLP-1RA维培那肽(派达康)正式获中国国家药监局批准上市，用于治疗2型糖尿病。派达康的上市将验证其商业化能力，而在研管线的持续推进则提供长期成长动力。在创新药投资的新周期中，派格生物凭借派达康的出色产品力和清晰的全球战略，已展现出成为代谢疾病领域龙头企业的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369267.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","BK1574","02565","06978"],"gpt_icon":0},{"id":"2583539480","title":"港股异动 | 派格生物医药-B(02565)最高涨超15% GLP-1减重药出海中东及非洲","url":"https://stock-news.laohu8.com/highlight/detail?id=2583539480","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583539480?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 11:28","pubTimestamp":1763004493,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B最高涨超15%，截至发稿，涨6.29%，报56.65港元，成交额994.16万港元。消息面上，派格生物医药上月宣布，授予阿联酋领先医药研发机构PDC FZ-LLC对其核心产品Visepegenatide 在中东及非洲地区的开发、分销、营销与商业化的独家许可。Visepegenatide  是派格生物自主研发的一款每周一次皮下注射的GLP-1受体激动剂，用于治疗2型糖尿病和体重管理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GLP","BK4144","161726","BK1161","02565","399441","BK4590"],"gpt_icon":0},{"id":"2581858847","title":"Tides 周递 | 全球多肽和寡核苷酸药物一周要闻（10.30-11.7）","url":"https://stock-news.laohu8.com/highlight/detail?id=2581858847","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581858847?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 08:30","pubTimestamp":1762561818,"startTime":"0","endTime":"0","summary":"目前全球尚无乙肝siRNA药物获批上市。作为对外许可交易对价一部分，上海民为生物将取得首笔投资款及近期里程碑款3500万美元以及Sidera公司9.99%的股权。根据临床开发和商业化销售金额，Sidera将向上海民为生物支付累计不超过10.1亿美元的里程碑款。该三期临床计划入组1205例Fontaine II级PAD患者，预计2028年6月完成。这一重大项目将扩大礼来的口服药物生产能力，并加强公司的全球供应链。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108083912a6e9e48a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108083912a6e9e48a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","NVO","LU2346227817.USD","IE00BD4GTT62.SGD","IE00BD4GTV84.USD","IE00BMG7P587.USD","BK4208","BK4599","06887","IE00BD4GTW91.USD","IE00BMG7P926.USD","LU0154236417.USD","IE00BMG7P819.SGD","IE00BKVL7J92.USD","LU1093756168.USD","BK4007","02565","BK4588","PEG","BK4143","IE00BMG7P694.USD","BK4585","IE00BZ1G4Q59.USD","ARC","BK4532"],"gpt_icon":1},{"id":"2580229492","title":"派格生物医药-B申请解散附属公司上海迈迹；恒瑞医药HRS-5965胶囊拟纳入优先审评｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2580229492","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580229492?lang=zh_cn&edition=fundamental","pubTime":"2025-11-04 07:14","pubTimestamp":1762211657,"startTime":"0","endTime":"0","summary":"｜2025年11月4日星期二｜NO.1派格生物医药申请自愿解散非全资附属公司上海迈迹派格生物医药-B宣布，公司已于2025年10月28日申请自愿解散公司的非全资附属公司上海迈迹生物医药科技有限公司（以下简称“上海迈迹”）。上海迈迹是一家于2017年6月26日成立的有限责任公司，从事GLP-2（一种参与肠道功能及代谢的肽类激素）的研究及开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511043553895263.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511043553895263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","01276","BK1515","LU0359201885.HKD","LU2543165471.USD","BK1191","LU0359202008.SGD","BK1574","02565","09939","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"1124311524","title":"一周港股牛熊榜 | 中东、非洲收获好消息，创新药企派格生物本周飙13%；政策与周期双轮驱动，英诺赛科升超11%；利润暴跌，中兴通讯本周跌超18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124311524","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124311524?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 17:31","pubTimestamp":1761903061,"startTime":"0","endTime":"0","summary":"据国际糖尿病联盟数据显示，中东及北非地区成年糖尿病患病率高达16.2%，位居全球首位。这一政策导向与近日闭幕的二十届四中全会精神一脉相承。英诺赛科近日宣布为800VDC电源构架提供全GaN电源解决方案，获得市场积极反应。受第三季度锂价回暖影响，赣锋锂业单季度归母净利润同比大增364.02%。前三季度实现营业收入102.75亿元，同比增长18.18%；归属于上市公司股东的净利润为4.70亿元，同比下降18.02%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00412","01772","02565","06168","06869","02577","01530","00763"],"gpt_icon":1},{"id":"2579843729","title":"港股异动 | 派格生物医药-B(02565)尾盘涨超20%再创新高 近期授出糖尿病药物于中东及非洲独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2579843729","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579843729?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 15:36","pubTimestamp":1761896169,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B尾盘涨超20%，高见62.25港元，再创上市新高。消息面上，派格生物医药近日公布，宣布与阿联酋领先医药研发机构PDC FZ-LLC达成战略合作，独家授予其在中东及非洲地区开发、分销、营销及商业化派格生物的核心产品Visepegenatide 。据悉，Visepegenatide  是派格生物自主研发的一款每周一次皮下注射的GLP-1受体激动剂，用于治疗2型糖尿病和体重管理。据国际糖尿病联盟数据显示，中东及北非地区成年糖尿病患病率高达16.2%，位居全球首位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","161726","BK1161","02565"],"gpt_icon":0},{"id":"2577870265","title":"派格生物医药-B10月23日主力净流出140.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2577870265","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577870265?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 16:15","pubTimestamp":1761207325,"startTime":"0","endTime":"0","summary":"10月23日, 派格生物医药-B股价跌2.75%，报收53.00元，成交金额589.5万元，换手率0.04%，振幅3.03%，量比0.61。派格生物医药-B今日主力资金净流出140.8万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.76%，主力资金累计净流出238.8万元；近20日主力资金累计净流出197.7万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161709a6c9990c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161709a6c9990c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2574267661","title":"派格生物医药-B(02565)：建议授出VISEPEGENATIDE (PB-119) 于中东及非洲的独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2574267661","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574267661?lang=zh_cn&edition=fundamental","pubTime":"2025-10-10 17:02","pubTimestamp":1760086973,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，公司欣然宣布已与阿拉伯联合酋长国的PDC FZ-LLC订立一份不具约束力的条款清单，内容有关公司产品Visepegenatide 的独家许可。根据建议条款，PDC将获授独家许可，以于中东及非洲地区开发、分销、营销及商业化该产品。中东及非洲地区为糖尿病及肥胖症治疗药物提供庞大且持续增长的市场。PDC为中东及非洲地区首屈一指的制药研发机构，于进行临床试验方面拥有卓越的往绩记录。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PB","IE00B64QTZ34.USD","399441","IE00BLDYK493.USD","161726","02565","BK1161","BK4211"],"gpt_icon":0},{"id":"2571356028","title":"派格生物医药-B：2025 中期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2571356028","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571356028?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 16:30","pubTimestamp":1759134606,"startTime":"0","endTime":"0","summary":"派格生物医药2025年上半年总亏损为人民币9,367万元，较去年同期的1.55亿元收窄40%。研发开支降至2,629万元，主要因PB-119处于NDA审评阶段，研发费用相应减少。期内管理开支为6,125万元，较去年同期的9,134万元下降34%。公司核心产品PB-119已于2025年5月进入国家药监局发补审评阶段，预计将于第三季度获得新药上市批准。公司已完成H股全球发售，募集资金净额约2.32亿港元，将主要用于PB-119的商业化及适应症扩展、PB-718的进一步开发以及其他管线产品研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092922484297b127dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092922484297b127dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2571635607","title":"派格生物医药-B09月29日遭主力抛售102.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2571635607","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571635607?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 16:15","pubTimestamp":1759133733,"startTime":"0","endTime":"0","summary":"09月29日, 派格生物医药-B股价跌1.27%，报收54.30元，成交金额812.2万元，换手率0.05%，振幅3.64%，量比0.34。派格生物医药-B今日主力资金净流出102.8万元，上一交易日主力净流出106.5万元。该股近5个交易日上涨5.54%，主力资金累计净流出62.4万元；近20日主力资金累计净流入104.8万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092916174497b07fb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092916174497b07fb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2570184887","title":"派格生物医药-B09月26日主力净流出106.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2570184887","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570184887?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 16:15","pubTimestamp":1758874513,"startTime":"0","endTime":"0","summary":"09月26日, 派格生物医药-B股价跌1.61%，报收55.00元，成交金额1126.9万元，换手率0.07%，振幅4.74%，量比0.45。派格生物医药-B今日主力资金净流出106.5万元，上一交易日主力净流出0万元。该股近5个交易日上涨10.66%，主力资金累计净流入40.4万元；近20日主力资金累计净流入486.4万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926161540a4456ec9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926161540a4456ec9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"2569763223","title":"港股异动 | 派格生物医药-B(02565)午前涨超5% GLP-1多靶点领域临床进度靠前 PB-718为公司旗下重磅品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2569763223","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569763223?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 11:52","pubTimestamp":1758599567,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B午前涨超5%，该股上市至今股价累计涨幅逾3.1倍。同时，上述部分MNC在GLP-1领域的技术路径、新靶点、新适应症等方面的布局仍有较大提升空间，该行看好国内细分领域布局药企出海BD机遇。浙商证券认为，在GLP-1多靶点领域国内部分管线临床进度靠前，有望持续诞生大BD事件。据了解，PB-718为派格生物医药旗下重磅产品，该药物是一款新型长效GLP-1/GCG双受体激动剂，其核心治疗方向是MASH治疗领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","BK4211","02565","PB","BK4144","BK4614","BK4590","HSCEI","161726","GLP","399441","BK1161"],"gpt_icon":1},{"id":"2568293297","title":"派格生物医药-B09月19日主力净流出49.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2568293297","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568293297?lang=zh_cn&edition=fundamental","pubTime":"2025-09-19 16:15","pubTimestamp":1758269729,"startTime":"0","endTime":"0","summary":"09月19日, 派格生物医药-B股价跌4.24%，报收49.70元，成交金额1450.6万元，换手率0.10%，振幅8.52%，量比0.75。派格生物医药-B今日主力资金净流出49.4万元，上一交易日主力净流入91.6万元。该股近5个交易日下跌2.09%，主力资金累计净流入34.0万元；近20日主力资金累计净流入88.2万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091916185795384496&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091916185795384496&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"2568403598","title":"派格生物医药-B09月18日主力净流入91.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2568403598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568403598?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 16:15","pubTimestamp":1758183322,"startTime":"0","endTime":"0","summary":"09月18日, 派格生物医药-B股价涨2.87%，报收51.90元，成交金额1966.4万元，换手率0.14%，振幅7.43%，量比1.11。派格生物医药-B今日主力资金净流入91.6万元，上一交易日主力净流出8.2万元。该股近5个交易日上涨0.78%，主力资金累计净流入83.4万元；近20日主力资金累计净流入120.0万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918161736979a93d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918161736979a93d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"2566981006","title":"派格生物医药-B09月10日获主力加仓37.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566981006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566981006?lang=zh_cn&edition=fundamental","pubTime":"2025-09-10 16:15","pubTimestamp":1757492131,"startTime":"0","endTime":"0","summary":"09月10日, 派格生物医药-B股价涨8.23%，报收51.95元，成交金额2954.2万元，换手率0.21%，振幅9.38%，量比1.24。派格生物医药-B今日主力资金净流入37.5万元，上一交易日主力净流入52.2万元。该股近5个交易日上涨20.25%，主力资金累计净流入199.0万元；近20日主力资金累计净流入411.7万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016173397850e8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091016173397850e8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}